Drugs / KT-474
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04772885 | Feb 2021 → Oct 2022 | atopic eczema, hidradenitis suppurativa | Kymera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06058156 | Nov 2023 → Oct 2025 | atopic eczema | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06028230 | Sep 2023 → Oct 2025 | hidradenitis suppurativa | Sanofi | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT-474 | “Drug: SAR444656 (KT-474)” NCT06028230 ↗ |
| Known as | SAR444656 | “KT-474 (SAR444656), an IRAK4 degrader, was studied in a randomized, double-blind, placebo-controlled phase 1 trial” PMID 37957373 ↗ Nov 2023 |
| Modality | Small molecule | “KT-474 is an oral heterobifunctional small molecule IRAK4 degrader” NCT04772885 ↗ |
| Route | Oral | “KT-474 or matching placebo oral tablet(s)” NCT04772885 ↗ |
| Target | IRAK4 | “KT-474 (SAR444656), an IRAK4 degrader” PMID 37957373 ↗ Nov 2023 |